title: Long-term efficacy of preseasonal grass pollen immunotherapy in children.
abstract: BACKGROUND
  In a previous controlled study we demonstrated that preseasonal grass pollen immunotherapy for three years was effective in children. In the current study we examined the same group of patients to see if there is still a benefit six years after discontinuation of treatment.
  
  
  METHODS
  Thirteen of 14 patients with previous specific immunotherapy (SIT) and 10 out of 14 patients of the control group were prospectively followed during the grass pollen season. Outcome measures were seasonal symptom scores for eyes, nose and chest, the use of symptomatic medication and visual analog scale. Objective measures included skin prick test reactivity to seasonal and perennial allergens and conjunctival provocation testing.
  
  
  RESULTS
  During the 13 week observation time scores for overall hayfever symptoms (P < 0.004) and individual symptoms for eyes (P < 0.02), nose (P < 0.04) and chest (P < 0.01) as well as combined symptom and medication scores (P < 0.002) remained lower in the group with previous SIT. Only 23% of patients with previous pollen-asthma who had received SIT experienced pollen-associated lower respiratory tract symptoms compared to 70% in the control group (P < 0.05). There was no significant difference in the use of pharmacological treatment during the pollen season except for asthma medication. The average visual analog scale was lower in the post-SIT group (P < 0.05). Six years after cessation of SIT the immediate skin response to grass pollen remained decreased compared to the reaction of the controls (P < 0.01). There was also a tendency for higher allergen concentration to provoke a conjunctival response in the post-SIT group but without reaching statistical significance. Eight years after commencement of SIT, 61% of the initially pollen-monosensitized children had developed new sensitization to perennial allergens compared to 100% in the control group (P < 0.05).
  
  
  CONCLUSIONS
  There is still a significant clinical benefit six years after discontinuation of preseasonal grass pollen immunotherapy in childhood. SIT in children with pollen-allergy reduces onset of new sensitization and therefore has the potential to modify the natural course of allergic disease.
authors.affiliation: Department of Pediatrics, Kantonsspital Aarau, Switzerland.
authors.forename: P A
authors.initials: PA
authors.lastname: Eng
authors.forename: M
authors.initials: M
authors.lastname: Reinhold
authors.forename: H P E
authors.initials: HP
authors.lastname: Gnehm
mesh_terms: D000293:Adolescent; D000485:Allergens / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D001985:Bronchial Provocation Tests; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010147:Pain Measurement; D008517:Phytotherapy; D006109:Poaceae / Q000009:adverse effects / Q000276:immunology; D011058:Pollen / Q000009:adverse effects / Q000276:immunology*; D011446:Prospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000209:etiology; D012621:Seasons; D012680:Sensitivity and Specificity; D012882:Skin Tests; D013557:Switzerland; D013995:Time; D016896:Treatment Outcome
chemical_list: D000485:Allergens